硝酸异山梨酯、维拉帕米和拉贝洛尔对肝硬化门静脉压力的影响。
Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.
作者信息
Freeman J G, Barton J R, Record C O
出版信息
Br Med J (Clin Res Ed). 1985 Aug 31;291(6495):561-2. doi: 10.1136/bmj.291.6495.561.
Abstract
The effects on portal pressure of the vasodilatory drugs isosorbide dinitrate and verapamil and of an alpha and beta blocking agent, labetalol, were assessed in 21 patients with cirrhosis and portal hypertension. The wedged hepatic venous pressure gradient (wedged minus free hepatic venous pressures) was used as an index of portal pressure and was not significantly changed by treatment with labetalol (n = 5) but was significantly decreased by verapamil (n = 6; p less than 0.05) and isosorbide dinitrate (n = 10; p less than 0.01). Long term administration of isosorbide dinitrate also had a significant effect (p less than 0.01).
摘要
在21例肝硬化和门静脉高压患者中评估了血管扩张剂硝酸异山梨酯和维拉帕米以及α和β阻滞剂拉贝洛尔对门静脉压力的影响。肝静脉楔压梯度（肝静脉楔压减去自由肝静脉压）用作门静脉压力指标，拉贝洛尔治疗（n = 5）对其无显著影响，但维拉帕米（n = 6；p < 0.05）和硝酸异山梨酯（n = 10；p < 0.01）使其显著降低。长期给予硝酸异山梨酯也有显著效果（p < 0.01）。
相似文献
1
Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.
Br Med J (Clin Res Ed). 1985 Aug 31;291(6495):561-2. doi: 10.1136/bmj.291.6495.561.
2
Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver.
J Int Med Res. 1989 Nov-Dec;17(6):560-4. doi: 10.1177/030006058901700610.
3
Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.
Crit Care Med. 1983 Jul;11(7):536-40. doi: 10.1097/00003246-198307000-00011.
4
Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
J Hepatol. 1996 Apr;24(4):423-9. doi: 10.1016/s0168-8278(96)80162-0.
5
Effect of sublingual isosorbide dinitrate on wedged hepatic venous pressure in cirrhotics with portal hypertension.
Indian J Gastroenterol. 1988 Jul;7(3):161-2.
6
Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis.
J Hepatol. 1987 Apr;4(2):174-80. doi: 10.1016/s0168-8278(87)80077-6.
7
Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension.
J Hepatol. 1989 May;8(3):316-24. doi: 10.1016/0168-8278(89)90029-9.
8
Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.
Gastroenterology. 1989 Apr;96(4):1110-8. doi: 10.1016/0016-5085(89)91630-2.
9
The hemodynamic effect of verapamil on portal hypertension in patients with postnecrotic cirrhosis.
Hepatology. 1986 May-Jun;6(3):423-6. doi: 10.1002/hep.1840060317.
10
Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats.
J Gastroenterol. 1994 Aug;29(4):460-8. doi: 10.1007/BF02361244.
引用本文的文献
1
Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.
World J Gastroenterol. 2020 Oct 28;26(40):6111-6140. doi: 10.3748/wjg.v26.i40.6111.
2
Effect of verapamil on nitric oxide synthase in a portal vein-ligated rat model: role of prostaglandin.
World J Gastroenterol. 2006 Apr 21;12(15):2351-6. doi: 10.3748/wjg.v12.i15.2351.
3
Effects of calcium antagonists on hepatic and systemic hemodynamics in awake portal hypertensive rats.
J Gastroenterol. 1996 Jun;31(3):366-72. doi: 10.1007/BF02355026.
4
Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.
Gut. 1995 Jan;36(1):104-9. doi: 10.1136/gut.36.1.104.
5
Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.
J Clin Invest. 1986 Aug;78(2):448-55. doi: 10.1172/JCI112596.
6
Effect and mechanism of action of isosorbide-5-mononitrate.
Gut. 1988 Jun;29(6):752-5. doi: 10.1136/gut.29.6.752.
7
The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis.
Br J Clin Pharmacol. 1988 Sep;26(3):273-7. doi: 10.1111/j.1365-2125.1988.tb05277.x.
8
Prophylaxis of first variceal hemorrhage in patients with liver cirrhosis.
Klin Wochenschr. 1986 Dec 15;64(24):1267-75. doi: 10.1007/BF01785707.
9
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
Drugs. 1989 Jul;38(1):19-76. doi: 10.2165/00003495-198938010-00003.
10
Nitrate tolerance. A review of the evidence.
Drugs. 1989 Apr;37(4):523-50. doi: 10.2165/00003495-198937040-00006.
本文引用的文献
1
Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.
Crit Care Med. 1983 Jul;11(7):536-40. doi: 10.1097/00003246-198307000-00011.
2
Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension.
Hepatology. 1982 Nov-Dec;2(6):757-62. doi: 10.1002/hep.1840020602.
3
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report.
Hepatology. 1984 May-Jun;4(3):355-8. doi: 10.1002/hep.1840040301.
4
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis.
N Engl J Med. 1983 Dec 22;309(25):1539-42. doi: 10.1056/NEJM198312223092502.
Zotero 插件